CT-388
Pharmaceutical compound
From Wikipedia, the free encyclopedia
CT-388 is a "biased" dual GLP-1 and GIP receptor agonist/modulator with minimal to no beta-arrestin coupling at either receptor and is designed to be administered as once weekly subcutaneous injection.[1] In a 24-week trial participants averaged 18.8 percent placebo adjusted weight loss. The drug is developed by Roche/Genentech.[2][3][4]
| Identifiers | |
|---|---|
| CAS Number | |